Pharma Two B

harma Two B is a clinical-stage pharmaceutical company that is developing differentiated and value-added products, based on reformulation of previously approved drugs. The Company's aim is to improve efficacy, safety and delivery profiles while addressing unmet medical needs and decreasing the timeline to FDA approval via the 505(b)(2) regulatory pathway. The Company's lead product P2B001 is being investigated as a treatment for early-stage Parkinson's disease (PD). P2B001 is a once daily, no titration, therapy for patients with PD to obtain good clinical efficacy with a low risk of side effects, as shown in the Phase IIb clinical trial. Pharma Two B is led by a highly experienced team, supported by prominent scientific and clinical key opinion leaders, and backed by a dedicated group of investors.